Document is current
Any future updates will be listed below
-
Authors
Heimberg, Graham https://orcid.org/0009-0002-6493-5721
Kuo, Tony
DePianto, Daryle J.
Salem, Omar https://orcid.org/0009-0005-1514-831X
Heigl, Tobias https://orcid.org/0000-0002-9591-8345
Diamant, Nathaniel https://orcid.org/0000-0002-1738-304X
Scalia, Gabriele
Biancalani, Tommaso https://orcid.org/0000-0001-9104-9755
Turley, Shannon J.
Rock, Jason R.
Corrada Bravo, Héctor
Kaminker, Josh https://orcid.org/0000-0001-5067-9275
Vander Heiden, Jason A. https://orcid.org/0000-0002-1474-310X
Regev, Aviv https://orcid.org/0000-0003-3293-3158
- License Information
-
More Information
Article History
Received: 13 August 2023
Accepted: 14 November 2024
First Online: 20 November 2024
Competing interests
: All of the authors are employees of Genentech or Roche. A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, was an scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. G.H., D.J.D., O.S., N.D., G.S., T.B., S.J.T., J.R.R., H.C.B., J.K., J.A.V.H. and A.R. have equity in Roche.
